To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Begins Day -1 and continues to Day +90 or Day +180 after transplant
Given Days +3 and +4 after transplant
Given Day 0 to Day +35 after transplant
Northside Hospital
Atlanta, Georgia, United States
RECRUITINGEfficacy in preventing CRS post transplant
Evaluate the incidence of CRS during the first 5 days following stem cell transplant by recording signs and symptoms based on CTCAE v5.0.
Time frame: 30 days
Severity of CRS after stem cell transplant
Record incidence of CRS by grading signs and symptoms using the CTCAE v5.0, the day of onset of CRS, the duration of CRS, and admissions to the hospital for these events
Time frame: 30 days
Safety of administering early immunosuppression
Record incidence of acute graft-versus-host disease at 6 months by using the NIH Grading Consensus system
Time frame: 6 months
Safety of administering early immunosuppression
Record incidence of chronic graft-versus-host disease at 1 year by using the NIH Grading Consensus system
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.